Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Accounts Payables (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Accounts Payables data on record, last reported at $26.9 million in Q3 2025.

  • For Q3 2025, Accounts Payables rose 50.03% year-over-year to $26.9 million; the TTM value through Sep 2025 reached $26.9 million, up 50.03%, while the annual FY2024 figure was $17.0 million, 65.65% up from the prior year.
  • Accounts Payables reached $26.9 million in Q3 2025 per NWBO's latest filing, up from $23.7 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $26.9 million in Q3 2025 and bottomed at $7.0 million in Q4 2021.
  • Average Accounts Payables over 5 years is $13.2 million, with a median of $11.9 million recorded in 2023.
  • Peak YoY movement for Accounts Payables: decreased 11.15% in 2022, then soared 65.65% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $7.0 million in 2021, then skyrocketed by 53.2% to $10.7 million in 2022, then fell by 4.15% to $10.2 million in 2023, then soared by 65.65% to $17.0 million in 2024, then surged by 58.38% to $26.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $26.9 million in Q3 2025, $23.7 million in Q2 2025, and $20.7 million in Q1 2025.